Regulatory Affairs & Registration

Our services:

  • Advice on strategic and operative aspects of drug development
  • Advice on the registration process
  • Development of registration strategies
  • Clarification of correct contact officials
  • Advice on timing of initial contact with the registration authorities
  • Facilitation of the initial contact with registration authorities
  • Support in preparation of meeting with officials
  • Negotiation of all steps to registration, and advice and support in their implementation
  • Support in all phases of contacts with the authorities, including dossier preparation and submission
  • Follow-up of submissions
  • Assistance with contacts to the US Food and Drug Administration (FDA)

 

Move fast towards launch!

 

< Our team

• 2022 – AMS are CTR- and MDR ready • 2022 – New unique AMS-ePRO® features launched • 2022 – Real-World Evidence focus in AMS Late-Stage Research • 2022 – AMS expanded its global reach • 2021 – DIGA dossier submission pioneer •

News